Liam Gibson

Lastest Stories by Liam Gibson

One of the first major biotech deals of the new year is offering investors a big bet on diabetes and obesity treatments.
A new natural gas play is coming to market. 
This week marks the 30th birthday of the first-ever U.S. exchange-traded fund, which ignited a new asset class and brought diversified portfolios to the masses. 
A niche healthcare play is coming to market, offering investors exposure to the animal kingdom.
A profitable renewables developer with a multiyear market-beating track record has joined the initial public offering cue. 
A new biopharma play is on its way as hypertension medicine developer Mineralys Therapeutics prepares to come to market.  The clinical-stage drug maker filed for an initial public offering (IPO)...
LiDAR company Hesai may light the way for Chinese IPOs in 2023.
Investors who see the Gulf remaining an economic safe harbor amid the global downturn this year can broaden their exposure to the sub-region through a new dedicated bond ETF.   
Skyward Insurance has raised the roof on its initial public offering (IPO), marking one of the first big deals of 2023.   Skyward priced its IPO on January 12 at $15, offering almost 9 million...
While storm clouds have gathered over tech and other sectors during the past year, renewable energy has become a bright spot on the investing map. 
A mega breakup that could shake up the consumer health care market is coming down the initial public offering pipeline.
A new "power play" is available through an exchange-traded fund investing deep in the critical minerals of the renewable energy revolution. 
As we approach the end of a tumultuous 2022, retail investors are wondering what's around the corner and whether they should adjust their portfolios for the new year.
What exactly does it mean to "cushion" one's career, and will this help workers ride out the turbulent period if a recession hits next year?
In a stunning reversal of fortunes (and a stark reminder of the value of diversified portfolios), tech-themed exchange-traded funds (ETFs) have been among the biggest losers of 2022.